These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23605174)

  • 1. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
    Viaene L; Behets GJ; Claes K; Meijers B; Blocki F; Brandenburg V; Evenepoel P; D'Haese PC
    Nephrol Dial Transplant; 2013 Dec; 28(12):3024-30. PubMed ID: 23605174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients.
    Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E
    Nephron; 2016; 132(3):181-90. PubMed ID: 26890570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
    Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM;
    Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
    Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
    Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
    Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
    Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients.
    Kirkpantur A; Balci M; Turkvatan A; Afsar B
    Nefrologia; 2016; 36(1):24-32. PubMed ID: 26546060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients.
    Evenepoel P; Goffin E; Meijers B; Kanaan N; Bammens B; Coche E; Claes K; Jadoul M
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4669-76. PubMed ID: 26505822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
    Pelletier S; Confavreux CB; Haesebaert J; Guebre-Egziabher F; Bacchetta J; Carlier MC; Chardon L; Laville M; Chapurlat R; London GM; Lafage-Proust MH; Fouque D
    Osteoporos Int; 2015 Aug; 26(8):2165-74. PubMed ID: 25910747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D.
    Wang XR; Yuan L; Zhang JJ; Hao L; Wang DG
    Nephrology (Carlton); 2017 Apr; 22(4):286-292. PubMed ID: 27165564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin: Another vascular calcification inhibitor?
    Claes KJ; Viaene L; Heye S; Meijers B; d'Haese P; Evenepoel P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3221-8. PubMed ID: 23788689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.
    Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y
    Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?
    Nowak A; Artunc F; Serra AL; Pollock E; Krayenbühl PA; Müller C; Friedrich B
    Kidney Blood Press Res; 2015; 40(3):266-76. PubMed ID: 25997652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients.
    Lee YT; Ng HY; Chiu TT; Li LC; Pei SN; Kuo WH; Lee CT
    Clin Chim Acta; 2016 Jan; 452():38-43. PubMed ID: 26522655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uremic toxicity and sclerostin in chronic kidney disease patients.
    Desjardins L; Liabeuf S; Oliveira RB; Louvet L; Kamel S; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
    Nephrol Ther; 2014 Nov; 10(6):463-70. PubMed ID: 25070604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease.
    Zeng C; Guo C; Cai J; Tang C; Dong Z
    Diab Vasc Dis Res; 2018 Mar; 15(2):99-105. PubMed ID: 29168393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients.
    Gong L; Zheng D; Yuan J; Cao L; Ni Z; Fang W
    Int Urol Nephrol; 2018 May; 50(5):955-961. PubMed ID: 29356934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.